These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 11385497)

  • 61. Inhibition of Pore-Forming Proteins.
    Omersa N; Podobnik M; Anderluh G
    Toxins (Basel); 2019 Sep; 11(9):. PubMed ID: 31546810
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effects of introducing a single charged residue into the phenylalanine clamp of multimeric anthrax protective antigen.
    Janowiak BE; Fischer A; Collier RJ
    J Biol Chem; 2010 Mar; 285(11):8130-7. PubMed ID: 20061382
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge.
    Bielinska AU; Janczak KW; Landers JJ; Makidon P; Sower LE; Peterson JW; Baker JR
    Infect Immun; 2007 Aug; 75(8):4020-9. PubMed ID: 17502384
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Evaluation of combinatorial vaccines against anthrax and plague in a murine model.
    DuBois AB; Freytag LC; Clements JD
    Vaccine; 2007 Jun; 25(24):4747-54. PubMed ID: 17482725
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Direct inhibition of T-lymphocyte activation by anthrax toxins in vivo.
    Comer JE; Chopra AK; Peterson JW; König R
    Infect Immun; 2005 Dec; 73(12):8275-81. PubMed ID: 16299324
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Protection against anthrax toxemia by hexa-D-arginine in vitro and in vivo.
    Sarac MS; Peinado JR; Leppla SH; Lindberg I
    Infect Immun; 2004 Jan; 72(1):602-5. PubMed ID: 14688144
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax.
    Sellman BR; Mourez M; Collier RJ
    Science; 2001 Apr; 292(5517):695-7. PubMed ID: 11326092
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Bioterrorism. Researchers question obsession with Cipro.
    Enserink M
    Science; 2001 Oct; 294(5543):759-61. PubMed ID: 11679638
    [No Abstract]   [Full Text] [Related]  

  • 69. Editorial.
    Mock M; Montecucco C
    Mol Aspects Med; 2009 Dec; 30(6):345-6. PubMed ID: 19733583
    [No Abstract]   [Full Text] [Related]  

  • 70. Microbiology. Fighting anthrax with a mutant toxin.
    Olsnes S; Wesche J
    Science; 2001 Apr; 292(5517):647-8. PubMed ID: 11330322
    [No Abstract]   [Full Text] [Related]  

  • 71. A dominant-negative therapy for anthrax.
    Leppla SH
    Nat Med; 2001 Jun; 7(6):659-60. PubMed ID: 11385497
    [No Abstract]   [Full Text] [Related]  

  • 72. Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis.
    Tournier JN; Ulrich RG; Quesnel-Hellmann A; Mohamadzadeh M; Stiles BG
    Expert Rev Anti Infect Ther; 2009 Mar; 7(2):219-36. PubMed ID: 19254170
    [TBL] [Abstract][Full Text] [Related]  

  • 73. New developments in vaccines, inhibitors of anthrax toxins, and antibiotic therapeutics for Bacillus anthracis.
    Beierlein JM; Anderson AC
    Curr Med Chem; 2011; 18(33):5083-94. PubMed ID: 22050756
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Interactions between anthrax toxin receptors and protective antigen.
    Scobie HM; Young JA
    Curr Opin Microbiol; 2005 Feb; 8(1):106-12. PubMed ID: 15694864
    [TBL] [Abstract][Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.